Despite their promise, basket trials come with challenges. One major hurdle is the heterogeneity of tumors; even if they share a common mutation, their responses to treatment can vary significantly. Additionally, the rarity of some mutations may result in small patient cohorts, complicating the statistical analysis and interpretation of results. Another challenge is the regulatory landscape, as approval processes for drugs tested in basket trials can differ from those for traditional trials.
